ArticleMedicine2026
Bionic sleep therapy combined with multimodal management for chronic insomnia with alcohol withdrawal-related symptoms: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
rationalePatients who use alcohol as a sleep aid may experience withdrawal-related insomnia and hyperarousal, which can reinforce continued drinking. Bionic sleep therapy (BST) is an exploratory intervention using intravenous anesthetic and sedative agents under close monitoring to induce a brief, controllable, sleep-like state. It may provide short-term support for sleep initiation during early alcohol withdrawal. PATIENT CONCERNS: A 71-year-old man had chronic insomnia for over 15 years and consumed 100 to 200 mL of Chinese baijiu nightly to initiate sleep, with additional alcohol after nocturnal awakenings. Repeated attempts to stop drinking were followed by worsening insomnia, restlessness, palpitations, diaphoresis, and intense alcohol craving, which improved after drinking. DIAGNOSES: Chronic insomnia with recurrent mild alcohol withdrawal-related symptoms and a high risk of complicated alcohol withdrawal.
interventionsThe patient underwent 2 monitored BST sessions on hospital days 1 and 2 under continuous cardiorespiratory monitoring. Propofol (1 mg/kg) was administered intravenously for rapid induction, followed by a 60-minute dexmedetomidine infusion via an IV pump at 0.2 to 0.4 μg/kg/h. Multimodal treatment was intensified on hospital day 2, including cognitive behavioral therapy for insomnia, medication adjustment, and adjunctive neuromodulation. OUTCOMES: During the overall multimodal treatment course, on the night of the first BST session, the patient initiated sleep without alcohol and returned to sleep after a nocturnal awakening without further drinking. Polysomnography showed a total sleep time of 373 minutes and sleep efficiency of 85.6%. Following the second session, he consumed approximately 20 mL of alcohol after a nocturnal awakening before returning to sleep; sleep diary-reported sleep efficiency was 90.6%. Vital signs remained stable during both sessions, and no apparent anesthesia- or sedation-related adverse events occurred. No further alcohol intake was recorded from hospital day 3 to day 7. At discharge, subjective sleep efficiency was 87.7%, with improvements in sleep initiation, maintenance, and some daytime symptoms. Postdischarge follow-up data were unavailable. LESSONS: BST using propofol and dexmedetomidine may warrant further investigation as an adjunct to multimodal management in patients with chronic insomnia, long-term alcohol use as a sleep aid, and withdrawal-related symptoms. However, improvements cannot be attributed specifically to BST, and its contribution and durability require prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.